Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Cox

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Orphanet Journal of Rare Diseases|November 18, 2025
Correction: Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Blood|September 13, 2003
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionRolf G Boot, Marri Verhoek, Maaike de Fost, et al.
Orphanet Journal of Rare Diseases|October 15, 2021
In-depth phenotyping for clinical stratification of Gaucher diseaseSimona D'Amore, Kathleen Page, Aimée Donald, et al.
Orphanet Journal of Rare Diseases|October 29, 2025
Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Blood|February 8, 2017
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapyTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
Blood Cells, Molecules & Diseases|December 22, 2009
Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher diseaseCarla E M Hollak, Johannes M F G Aerts, Nadia Belmatoug, et al.
Journal of Lipid Research|December 28, 2020
Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactionsDaphne E Boer, Mina Mirzaian, Maria J Ferraz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2012
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's diseaseRaquel Duran, Niccolo E Mencacci, Aikaterini V Angeli, et al.
Blood Cells, Molecules & Diseases|October 7, 2009
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseCarla E M Hollak, Stephan vom Dahl, Johannes M F G Aerts, et al.
Chembiochem : a European Journal of Chemical Biology|December 22, 2016
A Specific Activity-Based Probe to Monitor Family GH59 Galactosylceramidase, the Enzyme Deficient in Krabbe DiseaseAndré R A Marques, Lianne I Willems, Daniela Herrera Moro, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Orphanet Journal of Rare Diseases|November 18, 2025
Correction: Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Blood|September 13, 2003
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionRolf G Boot, Marri Verhoek, Maaike de Fost, et al.
Orphanet Journal of Rare Diseases|October 15, 2021
In-depth phenotyping for clinical stratification of Gaucher diseaseSimona D'Amore, Kathleen Page, Aimée Donald, et al.
Orphanet Journal of Rare Diseases|October 29, 2025
Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Blood|February 8, 2017
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapyTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
Blood Cells, Molecules & Diseases|December 22, 2009
Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher diseaseCarla E M Hollak, Johannes M F G Aerts, Nadia Belmatoug, et al.
Journal of Lipid Research|December 28, 2020
Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactionsDaphne E Boer, Mina Mirzaian, Maria J Ferraz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 11, 2012
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's diseaseRaquel Duran, Niccolo E Mencacci, Aikaterini V Angeli, et al.
Blood Cells, Molecules & Diseases|October 7, 2009
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseCarla E M Hollak, Stephan vom Dahl, Johannes M F G Aerts, et al.
Chembiochem : a European Journal of Chemical Biology|December 22, 2016
A Specific Activity-Based Probe to Monitor Family GH59 Galactosylceramidase, the Enzyme Deficient in Krabbe DiseaseAndré R A Marques, Lianne I Willems, Daniela Herrera Moro, et al.
Pageof 12